Eric Halioua MS, MBA

Eric Halioua is a serial entrepreneur with strong managerial, technological, fund-raising, and deal-making experience. Eric Halioua is President and CEO of PDC*line Pharma a clinical-stage biotech company that develops a new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic cells (PDC*line). He is also well Board member of the biotechnology companies Bioxodes (Belgium), HairClone (UK), and VitriCell (Belgium) and a member of the strategic advisory board of Innobiochips (France). He has raised more than €90 million throughout his career and has had numerous successes in the sale and initial public offering of biotechnology companies. He is co-inventor of the first GMP-approved mobile manufacturing unit for cell therapy.

Eric is co-founder of four biotechnology called Myosix (bought by Genzyme mid-2002), Murigenetics, HairClone, and Digital Orthopaedics. Eric worked for 12 years as a Principal in the Healthcare and Life Sciences Practice of Arthur D. Little where he led work in the areas of strategy, M&A, and technology & innovation management. He also worked as a project leader in the corporate R&D center of Astra-Zeneca. Eric holds two master's degrees (DEA and Magistère) in Pharmacology and Molecular Biology and an MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.